SAM
ALNY icon

Simplify Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Simplify Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,109
Closed -$441K – 146
2025
Q4 		$441K Buy
1,109
+335
+43% +$148K 0.01% 104
2025
Q3 		$353K Buy
+774
New +$315K 0.01% 111
2023
Q2 		– Sell
-1,072
Closed -$215K – 117
2023
Q1 		$215K Sell
1,072
-320
-23% -$67.3K 0.03% 109
2022
Q4 		$331K Buy
1,392
+112
+9% +$23.9K 0.05% 62
2022
Q3 		$256K Buy
+1,280
New +$244K 0.03% 69

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplify Asset Management's ALNY Position: Q1 2026 in Review

Simplify Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,109 shares — an estimated $441K sold.

Simplify Asset Management first reported a position in ALNY in Q3 2022 and held it in 5 quarters. The position peaked at $441K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Simplify Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Simplify Asset Management sold 1,109 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $441K.
  • Simplify Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Simplify Asset Management's Alnylam Pharmaceuticals position peaked at $441K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Simplify Asset Management's 13F filing for Q1 2026, filed 27 Apr 2026.